Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BF Spiromax versus Symbicort Turbohaler versus placebo on short-term lower leg growth in prepubescent children with persistent asthma
2010-019082-29Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol, budesonide and Placebo-COD Research Private Ltd in asthma and persistent asthma (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Primary efficacy endpoint. Started Jul 2010; status: completed.
02
Drugs
budesonide + formoterolbudesonidePlacebo-COD Research Private Ltd
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2010-019082-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019082-29.